Walters-Hoffert Lisa 4

What Happened
Lisa Walters-Hoffert, a director of Kiora Pharmaceuticals (KPRX), was granted an option to acquire 25,000 shares on June 10, 2026. The Form 4 records the award as a derivative grant (25,000 @ $0.00), meaning no cash was paid at the time of the grant and this is an equity award rather than a market purchase or sale.

Key Details

• Transaction date: June 10, 2026; Form filed: June 12, 2026 (filed within the SEC 2-business-day window).
• Transaction type: Award/grant of option to purchase common stock (reported as derivative).
• Amount: Option to acquire 25,000 shares; Form shows $0.00 for the acquisition value.
• Shares owned after transaction: Not specified in the provided filing summary.
• Footnote: The option was granted under Kiora’s 2024 Equity Incentive Plan and "will become fully exercisable on June 10, 2027." (vesting/exercise schedule noted in the filing)

Context
This was a grant of an option (compensation/retention award), not an exercise or open-market purchase—such grants are common for directors and reflect compensation, not an immediate cash investment or sale. The option must vest/become exercisable before the holder can buy shares; the filing does not indicate any immediate sale of shares.